A DRUG that could improve survival rates for children with a rare form of cancer has been approved for use by the NHS in Scotland.
Dinutuximab beta – also known as Qarziba – is expected to benefit seven children with neuroblastoma per year.
The disease is a cancer of the nerve cells, occurring mainly in very young children.
Neuroblastoma UK chairman Tony Heddon said: “The fact that more children will now be able to potentially benefit from this immunotherapy will provide much-needed reassurance for families affected across Scotland.
“Children battling this disease need all the help they can get.”
Children with neuroblastoma can suffer a range of symptoms including nausea and vomiting, bone pain, weight loss, bleeding and kidney damage.
The drug can improve survival rates and potentially delay the progression of the disease for patients who have not responded to initial treatments.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here